
    
      Eligible patients will be randomly assigned to receive, in a blinded manner, two infusions of
      either eptinezumab or placebo in a cross-over manner during the Placebo-controlled Period and
      Active Treatment Period of the study.

      The total duration of the study is 24 weeks, including a safety follow up period of 8 weeks.
    
  